Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Provided By PR Newswire
Last update: May 27, 2025
Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026
Read more at prnewswire.comNASDAQ:RNTX (9/11/2025, 8:11:49 PM)
1.08
-0.11 (-9.24%)
190.69
+6.82 (+3.71%)
Find more stocks in the Stock Screener
